In vitro Pb exposure disturbs the balance between Aβ production and elimination: The role of AβPP and neprilysin

NeuroToxicology

Volumn 32, Issue 3, 2011, Pages 300-306

  Huang, Hui ^a,b   Bihaqi, Syed Waseem ^a   Cui, Liuxin ^b   Zawia, Nasser H ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Amyloid precursor protein; A ; Alzheimer's; Neprilysin; Pb; SH SY5Y cells

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; LEAD; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA;

ARTICLE; CELL COUNT; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; IN VITRO STUDY; METAL BINDING; NEURITE; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS; UPREGULATION;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME REPRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEPRILYSIN; NEURONS; ORGANOMETALLIC COMPOUNDS; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; UP-REGULATION;

PRIMATES; RODENTIA;

EID: 79952470359     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2011.02.001     Document Type: Article

References (47)

1. Adlard P.A., Bush Al. Metal and Alzheimer's disease. J Alzheimers Dis 2006, 10:145-163.
2. Akiyama H., Kondo H., Ikeda K., Kato M., McGeer P.L. Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition. Brain Res 2001, 902:277-281.
3. Basha M.R., Wei W., Brydie M., Razmiafshari M., Zawia N.H. Lead-induced developmental perturbations in hippocampal Sp1 DNA-binding are prevented by zinc supplementation: in vivo evidence for Pb and Zn competition. Int J Dev Neurosci 2003, 21:1-12.
4. Basha M.R., Wei W., Bakheet S.A., Benitez N., Siddiqi H.K., Ge Y.W., et al. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 2005, 25:823-829.
5. Belyaev N.D., Nalivaeva N.N., Makova N.Z., Turner A.J. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep 2009, 10:94-100.
6. Braun J.M., Kahn R.S., Froehlich T., Auinger P., Lanphear B.P. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect 2006, 114:1904-1909.
7. Counter S.A., Buchanan L.H., Ortega F. Neurocognitive impairment in lead-exposed children of Andean lead-glazing workers. J Occup Environ Med 2005, 47:306-312.
8. El-Amouri S.S., Zhu H., Yu J., Gage F.H., Verma I.M., Kindy M.S. Neprilysin protects neurons against Abeta peptide toxicity. Brain Res 2007, 1152:191-200.
9. El-Amouri S.S., Zhu H., Yu J., Marr R., Verma I.M., Kindy M.S. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol 2008, 172:1342-1354.
10. Farris W., Schutz S.G., Cirrito J.R., Shankar G.M., Sun X., George A., et al. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 2007, 171:241-251.
11. Garza A., Vega R., Soto E. Cellular mechanisms of lead neurotoxicity. Med Sci Monit 2006, 12:RA57-65.
12. Gervais F.G., Xu D., Robertson G.S., Vaillancourt J.P., Zhu Y., Huang J., et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic Abeta peptide formation. Cell 1999, 97:395-406.
13. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
14. Goedert M., Spillantini M.G. A century of Alzheimer's disease. Science 2006, 314:777-781.
15. Heber S., Herms J., Gajic V., Hainfellner J., Aguzzi A., Rulicke T., et al. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci 2000, 20:7951-7963.
16. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003, 60:1119-1122.
17. Higuchi M., Iwata N., Saido T.C. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. Biochim Biophys Acta 2005, 1751:60-67.
18. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001, 292:1550-1552.
19. Jamsa A., Hasslund K., Cowburn R.F., Backstrom A., Vasange M. The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation. Biochem Biophys Res Commun 2004, 319:993-1000.
20. Jones L.G., Prins J., Park S., Walton J.P., Luebke A.E., Lurie D.I. Lead exposure during development results in increased neurofilament phosphorylation, neuritic beading, and temporal processing deficits within the murine auditory brainstem. J Comp Neurol 2008, 506:1003-1017.
21. Kanemitsu H., Tomiyama T., Mori H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 2003, 350:113-116.
22. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
23. Kounnas M.Z., Danks A.M., Cheng S., Tyree C., Ackerman E., Zhang X., et al. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010, 67:769-780.
24. Lahiri D.K., Farlow M.R., Sambamurti K., Greig N.H., Giacobini E., Schneider L.S. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 2003, 4:97-112.
25. Li M., Sun M., Liu Y., Yu J., Yang H., Fan D., et al. Copper downregulates neprilysin activity through modulation of neprilysin degradation. J Alzheimers Dis 2010, 19:161-169.
26. Lidsky T.I., Schneider J.S. Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain 2003, 126:5-19.
27. Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., Markesbery W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998, 158:47-52.
28. Luo Y., Niu F., Sun Z., Cao W., Zhang X., Guan D., et al. Altered expression of Abeta metabolism-associated molecules from d-galactose/AlCl(3) induced mouse brain. Mech Ageing Dev 2009, 130:248-252.
29. Marr R.A., Guan H., Rockenstein E., Kindy M., Gage F.H., Verma I., et al. Neprilysin regulates amyloid beta peptide levels. J Mol Neurosci 2004, 22:5-11.
30. Maynard C.J., Cappai R., Volitakis I., Cherny R.A., White A.R., Beyreuther K., et al. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 2002, 277:44670-44676.
31. McGlothan J.L., Karcz-Kubicha M., Guilarte T.R. Developmental lead exposure impairs extinction of conditioned fear in young adult rats. Neurotoxicology 2008, 29:1127-1130.
32. Migliore L., Coppede F. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res 2009, 667:82-97.
33. Miners J.S., Van Helmond Z., Chalmers K., Wilcock G., Love S., Kehoe P.G. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2006, 65:1012-1021.
34. Murphy M.P., Levine H. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis 2009.
35. Pardossi-Piquard R., Petit A., Kawarai T., Sunyach C., Alves da Costa C., Vincent B., et al. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron 2005, 46:541-554.
36. Rivera-Mancia S., Perez-Neri I., Rios C., Tristan-Lopez L., Rivera-Espinosa L., Montes S. The transition metals copper and iron in neurodegenerative diseases. Chem Biol Interact 2010, 186:184-199.
37. Roher A.E., Chaney M.O., Kuo Y.M., Webster S.D., Stine W.B., Haverkamp L.J., et al. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 1996, 271:20631-20635.
38. Roques B.P., Fournie-Zaluski M.C., Soroca E., Lecomte J.M., Malfroy B., Llorens C., et al. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 1980, 288:286-288.
39. Sambamurti K., Suram A., Venugopal C., Prakasam A., Zhou Y., Lahiri D.K., et al. A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res 2006, 3:81-90.
40. Selkoe D.J. Amyloid protein and Alzheimer's disease. Sci Am 1991, 265:68-71. 4-6 8.
41. Shih R.A., Hu H., Weisskopf M.G., Schwartz B.S. Cumulative lead dose and cognitive function in adults: a review of studies that measured both blood lead and bone lead. Environ Health Perspect 2007, 115:483-492.
42. Tanzi R.E., Bertram L. Alzheimer's disease: the latest suspect. Nature 2008, 454:706-708.
43. Toscano C.D., Guilarte T.R. Lead neurotoxicity: from exposure to molecular effects. Brain Res Brain Res Rev 2005, 49:529-554.
44. White L.D., Cory-Slechta D.A., Gilbert M.E., Tiffany-Castiglioni E., Zawia N.H., Virgolini M., et al. New and evolving concepts in the neurotoxicology of lead. Toxicol Appl Pharmacol 2007, 225:1-27.
45. Wu J., Basha M.R., Brock B., Cox D.P., Cardozo-Pelaez F., McPherson C.A., et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 2008, 28:3-9.
46. Zawia N.H. Transcriptional involvement in neurotoxicity. Toxicol Appl Pharmacol 2003, 190:177-188.
47. Zou L.B., Mouri A., Iwata N., Saido T.C., Wang D., Wang M.W., et al. Inhibition of neprilysin by infusion of thiorphan into the hippocampus causes an accumulation of amyloid beta and impairment of learning and memory. J Pharmacol Exp Ther 2006, 317:334-340.